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ABSTRACT
Introduction: Albiglutide, a selective once-
weekly glucagon-like peptide-1 receptor
agonist, is being developed for the treatment
of type 2 diabetes mellitus. Albiglutide’s effect
on cardiac repolarization (QTc interval) was
assessed in a randomized, double-blind,
placebo-controlled, parallel-group study in
healthy subjects with a nested crossover
comparison for moxifloxacin.
Methods: Subjects were randomized to
albiglutide (n = 85) or placebo (n = 89) and
received injections of 30 mg albiglutide or
placebo on Days 1 and 8 and 50 mg
albiglutide or placebo on Days 15, 22, 29, and
36. In the placebo group, moxifloxacin was
administered on Day -1 in half the subjects and
on Day 40 in the other half. Blood samples for
albiglutide plasma concentration were drawn
on Days 4 and 39 and serial ECGs were extracted
from continuous recordings on Days -2
(baseline), -1, 4, 39, and 40.
Results: Demographics were generally similar
between albiglutide and placebo subjects: mean
age was 29 years and BMI 25 kg/m2. Mean
change-from-baseline QTcI (DQTcI, which was
corrected for individual heart rate) on Day 4
after a single dose of albiglutide 30 mg and on
Day 39 after repeat dosing with albiglutide
50 mg once weekly was similar to the placebo
response. The placebo-corrected DQTcI
(DDQTcI) on both albiglutide doses was small
with the largest DDQTcI of 1.1 ms (upper bound
of 90% CI 3.8 ms) on Day 4 and -0.6 ms (upper
bound of CI 1.8 ms) on Day 39. Moxifloxacin
caused the largest mean effect on DDQTcI of
10.9 ms and the lower bound of the CI was
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above 5 ms at all preselected timepoints,
thereby demonstrating assay sensitivity.
Albiglutide was well tolerated and there were
no clinically relevant differences in safety data
between albiglutide and placebo.
Conclusion: Albiglutide at doses up to 50 mg in
healthy subjects did not prolong the QTc
interval.
Keywords: Albiglutide; GLP-1 receptor agonist;
Healthy volunteers; QTc interval; Thorough QT
study; Type 2 diabetes mellitus
INTRODUCTION
Albiglutide is a novel glucagon-like peptide-1
(GLP-1) receptor agonist generated through
genetic fusion of 2 tandem copies of modified
human GLP-1 to human albumin. The GLP-1
sequence has been modified to confer resistance
to dipeptidyl peptidase-IV (DPP-IV)-mediated
proteolysis. The human albumin moiety of the
recombinant fusion protein together with the
DPP-IV resistance greatly extends the half-life to
*5 days, allowing once-weekly dosing [1, 2].
Albiglutide retains the glucose-dependent
insulinotropic activities of GLP-1 in vitro and
in vivo [3] and is being developed for the
treatment of type 2 diabetes mellitus (T2DM).
In recent years, some non-antiarrhythmic
drugs have been found to delay cardiac
repolarization as shown by prolongation of the
heart rate-corrected QT interval (QTc) on a
standard 12-lead electrocardiogram (ECG) [4].
QTc prolongation can result in life-threatening
ventricular proarrhythmias, such as torsade de
pointes, which can degenerate into ventricular
fibrillation and cause sudden death. As a
consequence, the International Conference on
Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use
(ICH) issued the E14 guidance in 2005 for
clinical evaluation of QT/QTc interval
prolongation and proarrhythmic potential for
non-antiarrhythmic drugs [5, 6]. This guidance
provides recommendations on the design,
conduct, analysis, and interpretation of a
designated study for the assessment of a new
drug’s potential effect on QTc interval, the so-
called ‘‘thorough QT/QTc (TQT) study’’. A TQT
study is typically conducted in healthy
volunteers and should be placebo-controlled
and designed to address potential bias,
including the use of randomization and
appropriate blinding. A TQT study should also
include a positive control to demonstrate that
the study is sensitive enough to detect small
QTc changes. The vast majority of TQT studies
utilize moxifloxacin, a fluoroquinolone
antibiotic, for this purpose. Moxifloxacin
causes *7.5–18 ms QTc prolongation [7–9],
and specific criteria have been established to
confirm ‘‘assay sensitivity’’ with this drug in
TQT studies [5].
Based on the long half-life of albiglutide, a
parallel design was chosen for this TQT study.
To effectively use subjects dosed with placebo or
the positive control, a nested crossover
comparison was used for demonstration of
assay sensitivity [10]. Recently, several TQT
studies have used this design [11–14], which is
particularly useful for studies with an extended
treatment duration, which may be needed to
achieve sufficiently high plasma levels of the
drug or to improve the tolerability.
Gastrointestinal side effects are observed in the
GLP-1 receptor class, and in order to minimize
the potential for nausea and vomiting, which
could complicate the interpretation of a TQT
study, subjects in the current study received
subcutaneous (SC) albiglutide 30 mg once
weekly (or placebo) for the first 2 weeks and
then 50 mg once weekly (or placebo) for the
remaining 4 weeks. The assessment of a
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potential QT effect of albiglutide was
determined at the maximum intended clinical
dose of 50 mg once weekly, which was also the
approach used in the TQT studies from others in
the GLP-1 receptor class [15, 16].
The objective of the study was to assess the
effect of albiglutide 50 mg subcutaneously
injected weekly on cardiac repolarization
measured as the QTc interval after 6 weeks of
treatment.
This study was performed to evaluate
whether albiglutide 50 mg subcutaneously
injected weekly had an effect on cardiac
repolarization in terms of prolongation of the
QTc interval, an effect that could cause
proarrhythmias in susceptible patients. In line
with regulatory expectations, the study was
designed to allow exclusion of a QTc effect
exceeding the threshold of clinical and
regulatory concern (10 ms).
METHODS
The study protocol was approved by an
institutional review board and conducted in
accordance with the Declaration of Helsinki.
Written informed consent was obtained from
all subjects prior to any study-related
procedures.
One hundred and seventy (170) non-
smoking male and female healthy adult
subjects (18–45 years, inclusive) were planned
for enrollment in the study to ensure at least 70
subjects per treatment group. Subjects were to
be in good health as judged by the absence of
clinically significant diseases or clinically
significant abnormal laboratory values. ECG-
related exclusion criteria included absence of
cardiovascular disease or history of arrhythmias
and QTc \450 ms.
Subjects were admitted to the clinical unit
on Days -3 and 35 and remained in-house until
all procedures were completed on Days 5 and
41, respectively. On Days 1 and 8, subjects
received 30 mg SC albiglutide or matching
placebo and on Days 15, 22, 29, and 36,
subjects received a 50-mg injection of
albiglutide or matching placebo. Subjects
randomized to albiglutide received
moxifloxacin placebo on Days -1 and 40.
Moxifloxacin (400 mg oral) was given blindly
as a positive control in a nested (crossover)
design in the combined albiglutide placebo/
moxifloxacin group on Days -1 and 40. Half of
these subjects received moxifloxacin 400 mg on
Day -1 and moxifloxacin placebo on Day 40
and the other half received moxifloxacin
placebo on Day -1 and moxifloxacin 400 mg
on Day 40 (Fig. 1). All doses of study medication
were administered at approximately 9:00 AM.
ECG Methodology
Continuous ECGs were recorded on Days -2,
-1, 4, 39, and 40 using M12R ECG 12-lead
digital recorders (Global Instrumentation, LLC,
Manlius, NY). The continuous 12-lead ECG data
were stored on secure digital memory cards and
transferred to the central ECG laboratory
(iCardiac Technologies, Rochester, NY). ECGs
were extracted from the continuous recordings
at 1, 2, 3, 6, 12, and 24 h post-dosing. Subjects
were resting in the supine or semirecumbent
position for at least 15 min before each
timepoint from which ECGs were extracted.
The ECG assessment was performed on Day 4,
representing approximate mean peak plasma
level (Cmax) after a single 30-mg dose and on
Day 39, which represents approximate Cmax
after repeat 50-mg doses.
At each timepoint, up to 10 ECG replicates
were extracted with TQT Plus, a computer-
assisted algorithm utilizing quality and heart
rate stability criteria to extract ECG data from
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Fig. 1 a CONSORT ﬂow diagram and b study design. CONSORT Consolidated Standards of Reporting Trials
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continuous 24-h Holter recordings. All readable
cardiac cycles from these ECG replicates were
assessed for multiple quality metrics, including
beat stability, heart rate changes, noise, and
other parameters, and were categorized into
high- and low-confidence rank. All low-
confidence beats were fully reviewed and
adjudicated manually by ECG technicians
using pass–fail criteria. The beats found
acceptable by manual review were included
with the high-confidence rank beats in the
analysis. ECG interval measurements were
made using the High Precision QT
measurement technique with lead II as the
primary analysis lead. Categorical T-wave
morphology analysis and measurement of PR
and QRS intervals were performed manually in
3 of the 10 ECG replicates at each timepoint.
Final quality control and diagnostic
interpretations were performed by the study
cardiologist.
Pharmacokinetic Assessment
Blood samples for serial albiglutide
pharmacokinetic (PK) assessments were
obtained at the same timepoints as ECG
assessment on Days -2, -1, 4, 39, and 40.
Single blood samples for plasma trough
concentrations of albiglutide were also
obtained before dosing on Days 8, 15, 22, 29,
and 36. Plasma analyses for albiglutide
concentrations were performed by
GlaxoSmithKline (GSK) Department of Drug
Metabolism and PK (King of Prussia, PA) using
a chemiluminescent immunoassay. Plasma
samples were diluted 100-fold with sample
buffer before analysis. Albiglutide was captured
using a rabbit anti-human GLP-1 (7–36) amide
and detected using a rabbit anti-human serum
albumin (HSA) conjugated to biotin. Sample
concentrations were determined by
interpolation from the standard curve, which
was fitted using a weighted (1/x), 4-parameter
logistic equation. The validated range of this
assay (based on 10 lL of human plasma) is
50–1,500 ng/mL.
Statistical Analysis
The primary endpoint was the placebo-corrected
change-from-baseline QTc (DDQTc) on Day 39
using the heart rate correction method chosen
for the primary analysis, based on prospectively
defined criteria [DDQTcI (individual correction
change-from-baseline formula) or DDQTcF
(Fridericia’s correction change-from-baseline
formula)]. Secondary ECG endpoints included
DDQTc (by the primary method) on Day 4;
DDQTc on Day 4 and Day 39 for correction
methods not used as primary endpoint; effects
on heart rate, PR, and QRS intervals; and changes
in T/U-wave morphology and categorical QTc
outliers [change-from-baseline QTc (DQTc)[30
and[60 ms and QTc[450,[480, and[500 ms].
Other endpoints included PK and safety
parameters [clinical laboratory evaluations,
vital signs, physical examination, and adverse
events (AEs)].
The QT corrected for individual heart rate
(QTcI) was derived as follows: QT/RR pairs from
all six nominal timepoints on Day -2 (baseline)
from each subject were used to derive that
subject’s individual correction formula. Based
on QT/RR pairs from all subjects, the log(RR)
coefficient bi was derived from linear mixed-
effects modeling: log(QT) = log(a) ? b 9 log(RR/
1,000) with gender included as a fixed effect and
subject included as a random effect for both
intercept and slope. The log(RR) coefficient for
each subject, bi, was then used to calculate the
QTcI for each subject as follows:
QTcI ¼ QT RR=1;000ð Þbi :
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To determine which QTc method (QTcF or
QTcI) provided the best heart rate correction on
treatment, the relationship between QTc (QTcF
and QTcI) and the RR interval was investigated
using on-treatment data from Day -1 and 40
for moxifloxacin and moxifloxacin placebo and
Days 4 and 39 for albiglutide and albiglutide
placebo by linear regression modeling:
QTc = a ? b 9 RR. The RR coefficient for each
subject, bi, was used to calculate the average
sum of squared slopes for each of the different
QT-RR correction methods and each treatment
(moxifloxacin, albiglutide placebo, and
albiglutide). The correction method that
resulted in the average on-treatment slope
closest to 0 for Day 39 albiglutide and
albiglutide placebo (the smallest average sum
of squared slopes averaged across the 2
treatment groups) was deemed the most
appropriate heart rate correction method, as
suggested by Tornoe et al. [17], and was
therefore to be used as the primary endpoint.
For the primary analysis of ECG effects of
albiglutide vs. placebo, time-matched values on
Day -2 were used as baseline. For the nested
crossover comparison of moxifloxacin vs.
moxifloxacin placebo to demonstrate assay
sensitivity, the change from baseline was
computed based on the corresponding period
baseline, i.e., for Day -1, time-matched values
on Day -2 were used and for Day 40, values on
Day 39 were used as the period baseline. An
alternative baseline was also explored for this
comparison: For Day -1, Day 40 was used as
baseline and for Day 40, Day -1 was the
baseline, i.e., using the same duration
(40 days) between baseline and assessment as
for the primary analysis.
The statistical framework was to demonstrate
non-inferiority of albiglutide on QTc as
compared with placebo. Statistical analysis of
the ECG data was performed using the statistical
software R for Windows (Version 2.13.0 or
higher). The primary endpoint (DDQTc at each
timepoint post-dosing) was analyzed using a
linear mixed-effects model with fitting terms of
treatment, time, and treatment-by-time
interaction. Subject was included in the model
as a random effect. Baseline QTc was included as
a covariate. Replicates at each timepoint were
averaged before the analysis. Least-square
means and corresponding 90% CIs were
constructed at each timepoint. In addition, a
similar linear mixed-effects model was repeated
with inclusion of gender as a fixed effect.
Descriptive statistics were provided for the
analysis of heart rate, PR, and QRS intervals.
For the purpose of demonstrating assay
sensitivity as described by the ICH E14
Questions & Answers document [5], the
contrast in treatment DDQTc = ‘‘moxifloxacin-
placebo’’ at 1, 2, and 3 h postdosing was tested
against the 1-sided null hypothesis
DDQTc\5 ms at the 5% level. Multiplicity was
controlled through the Hochberg procedure
[18]. If after this procedure, DDQTc was
significantly [5 ms for at least 1 timepoint,
assay sensitivity was to be considered to have
been shown. In addition, 2-sided 90% CIs were
obtained for the contrast at all timepoints for
descriptive purposes and used in the figures.
The relationship between albiglutide plasma
concentrations and the primary endpoint
DDQTcI was quantified using a linear mixed-
effects modeling approach. Three linear models
were explored: (1) a model with an intercept; (2)
a model with mean intercept fixed to 0 (with
variability); and (3) a model with no intercept.
Time-matched concentration was included in
the model as covariate and subjects as a random
effect for both intercept and slope, whenever
applicable. A plot of standardized residuals
versus fitted values was used to examine
departure from model assumptions. The
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normal Q–Q plots of the random effects and the
within-subject errors were used to investigate the
normality of the random effects and the within-
subject errors, respectively. A final assessment of
the adequacy of the linear mixed-effects model
was provided by a goodness-of-fit plot (i.e., the
observed concentration quantile-DDQTcI plot)
as proposed by Tornoe et al. [17]. Such a plot was
used to check the assumption of linearity
between albiglutide concentrations and DDQTcI
and how well the predicted DDQTcI matched the
observed data in the regions of interest.
RESULTS
A total of 174 subjects were randomized, of
whom 85 were enrolled in the albiglutide group
and 89 in the placebo group; with a mean age of
29.5 years (range 18–45 years) and a mean BMI
of 25.2 kg/m2 (range 19.3–30.0 kg/m2). ECG
parameters at baseline were comparable
between treatment groups. With the exception
of gender (males, 67% in albiglutide group vs.
50% in placebo group) and race (White/
Caucasian/European heritage, 61.2% in
albiglutide group and 70.5% in placebo
group), demographics and baseline
characteristics were generally similar between
subjects across treatment groups. Seventy-eight
subjects (91.8%) who received albiglutide and
78 subjects (85.4%) who received albiglutide
placebo completed the study.
Electrocardiographic Effects of Albiglutide
After repeat dosing with albiglutide 50 mg once
weekly, an increase in heart rate of
approximately 6–8 bpm was observed
(Table 1), whereas a single dose of albiglutide
30 mg was similar to placebo and moxifloxacin.
The slope estimate for QTcI across subjects
was somewhat higher [0.347; 90% confidence
interval (CI) 0.342, 0.354] than for QTcF (fixed
at 0.333). In the comparison between QTcI and
QTcF, QTcI consistently resulted in the lowest
average sum of squared slopes (SSS) across
treatments and was therefore selected as the
primary endpoint (Table 2). Albiglutide, when
given as a single 30-mg dose or as multiple
50-mg doses given once weekly, did not prolong
the QTc interval (Fig. 2). The largest mean
DDQTcI was B1.1 ms for both doses and the
upper bound of the 90% CI was \10 ms at all
post-dosing timepoints (Table 3). Results from
the analysis of QTcF were entirely consistent
with QTcI (data not shown).
When gender was included as an additional
fixed effect in the statistical model, results were
comparable and conclusions remain the same
(data not shown). The study’s ability to
demonstrate small QTc changes was confirmed
Table 1 Effect on heart rate, QRS, and PR intervals
Range of the placebo-corrected mean change from baseline
Heart rate (bpm) QRS interval (ms) PR interval (ms)
Albiglutide 30 mg 0.6 to 3.0 0.3 to 0.5 0.6 to 3.9
Albiglutide 50 mg 6.0 to 7.8 0.6 to 1.1 1.5 to 4.5
Moxiﬂoxacin 0.5 to 3.9 0.0 to 0.7 -3.3 to -0.2
Days 4 and 39 correspond to the approximate Cmax following a single 30-mg dose and repeat 50-mg once-weekly dosing,
respectively
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by the moxifloxacin response with a largest
mean DDQTcI of 10.9 ms and the lower bound
of the 90% CI [5 ms at all prespecified
timepoints (1, 2, and 3 h; Table 3). The effect
of moxifloxacin on DDQTcI analyzed with the
alternative baseline (with 40 days between
baseline and moxifloxacin/placebo assessment)
showed a similar mean peak effect (13 ms).
Despite somewhat wider 90% CIs of the
estimate as compared with the period-specific
baseline, the lower bound exceeded 5 ms at all
prespecified timepoints (data not shown), i.e.,
the criteria for assay sensitivity were also met
using the alternative baseline.
The variability of the QTc measurements
calculated as the between-subject SD of DQTcI
Table 2 Average sum of






mean of squared individual slopes
QTcF QTcI
Day 4 albiglutide 0.0022 0.0018
Day 39 albiglutide 0.0033 0.0029
Moxiﬂoxacin 0.0036 0.0028
Day 4 albiglutide placebo 0.0024 0.0017
Day 39 albiglutide placebo 0.0029 0.0022
Moxiﬂoxacin placebo 0.0014 0.0008
Fig. 2 Placebo-corrected change from baseline (DDQTcI) after a single (30 mg) and multiple doses (50 mg) of albiglutide
and a single oral dose of 400 mg moxiﬂoxacin
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averaged over all timepoints was comparable
across treatments: for both albiglutide doses
and placebo 7.4 ms, for moxifloxacin 6.1 ms,
and for moxifloxacin using the alternative
baseline 8.0 ms.
In the PK/QTc analysis, it was demonstrated
that a linear model with fixed intercept provided
the best fit of the data. A negative relation
between albiglutide plasma levels and DDQTcI
could be shown with a slope of -0.0003 ms/ng/
mL (90% CI -0.0004, -0.0001; P = 0.0008).
Using this model, the projected DDQTcI at the
geometric mean peak plasma concentration
(10,200 ng/mL) could be estimated to -2.51 ms
(90% CI -3.65, -1.37; Fig. 3). These results are
consistent with the conclusions from the
primary analysis that albiglutide at doses
B50 mg did not prolong the QTc interval.
There were no subjects with a QTcI value
exceeding 450 ms or a DQTcI exceeding 30 ms
on albiglutide treatment and no treatment-
emergent changes in T-wave morphology were
noted on albiglutide treatment.
Change-from-baseline PR (DPR) was
somewhat larger on albiglutide than on
placebo, and placebo-corrected, change-from-
Table 3 Placebo-corrected change from baseline across treatment groups and timepoints
Time (h) Day 4 albiglutide (ms) Day 39 albiglutide (ms) Moxiﬂoxacin (ms)
Mean (SE) 90% CI Mean (SE) 90% CI Mean (SE) 90% CI
1 1.0 (1.6) -1.6, 3.7 -0.6 (1.5) -3.0, 1.8 10.8 (1.0) 9.1, 12.4
2 0.8 (1.6) -1.8, 3.5 -1.9 (1.5) -4.3, 0.5 10.9 (1.0) 9.2, 12.6
3 1.1 (1.6) -1.5, 3.8 -0.7 (1.5) -3.1, 1.8 10.8 (1.0) 9.2, 12.5
6 0.7 (1.6) -1.9, 3.3 -1.8 (1.5) -4.2, 0.6 9.9 (1.0) 8.2, 11.6
12 -1.2 (1.6) -3.9, 1.4 -3.1 (1.5) –5.5, -0.7 7.8 (1.0) 6.2, 9.5
24 0.8 (1.6) -1.9, 3.5 -2.4 (1.5) -4.9, 0.1 5.8 (1.1) 4.0, 7.5
Results from statistical modeling. Day 4 and Day 39 correspond to the approximate Cmax following a single 30-mg dose and
repeat 50-mg once-weekly dosing, respectively
CI conﬁdence interval, SE standard error of the mean, Cmax maximum concentration
Fig. 3 Goodness-of-ﬁt plot for observed and predicted
PK/DDQTcI relationship. Red and blue squares with
vertical bars denote the observed mean DDQTcI with 90%
CI within each plasma concentration decile (i.e., are based
on substantially fewer data points as compared with the
model); the widths of the CIs are therefore not directly
comparable. The solid black line with grey shaded area
denotes the model-predicted mean DDQTcI with 90% CI.
The horizontal red and blue lines with notches show the
range of plasma concentrations within each decile on
Days 4 and 39, respectively. CI conﬁdence interval, PK
pharmacokinetic, DDQTcI placebo-corrected change from
baseline, QTcI individual heart rate-corrected QT interval
Diabetes Ther (2014) 5:141–153 149
baseline PR (DDPR) varied between 0.6 and
3.9 ms on albiglutide 30 mg and between 1.5
and 4.5 ms on albiglutide 50 mg. No effect on
the QRS interval was observed with DDQRS
B1.1 ms at all post-dosing timepoints (Table 1).
Safety
Overall, 41.2% of the subjects in the albiglutide
group and 39.3% in the albiglutide placebo group
reported an AE. The most common AEs reported
were nausea, vomiting, and headache (each
8.2%) with albiglutide and headache, nausea
(both 11.4%), and contact dermatitis (8.0%) with
placebo. Four subjects experienced AEs that led
to discontinuation of study drug: asthma (serious
AE; albiglutide placebo), maculopapular rash
(albiglutide), vomiting (albiglutide placebo),
and drug eruption (maculopapular rash due to
moxifloxacin). Serious AEs were reported in 2
subjects: acute appendicitis 15 days after the last
dose of albiglutide and asthma of moderate
severity on Day 1 in a subject in the placebo
group who received moxifloxacin on Day -1.
Overall evaluations of other laboratory tests,
vital sign measurements, ECGs, and physical
exams were generally unremarkable; no
clinically meaningful differences were observed
between the groups.
DISCUSSION
This Phase I, randomized, double-blind, single-
center, parallel, nested crossover study
investigated the effect of treatment with
albiglutide given weekly over 6 weeks compared
with albiglutide placebo on cardiac repolarization
as determined by the QTc in healthy male and
female subjects. Both genders were enrolled into
the study since women have longer baseline QTc
and may bemore susceptible to drug-induced QTc
prolongation [19]; if QTc prolongation is
observed, there is also a regulatory expectation
to analyze the data by gender (see Q&A #8 in [5]).
The ICH guidance documents state that a parallel
design is recommended for drugs with long
elimination half-lives to achieve steady state [6].
In this study, the parallel study design was chosen
in light of the long half-life of albiglutide
(*5 days) and the need for multiple doses to
achieve steady-state concentrations at clinically
relevant plasma exposures. This study
incorporated an alternative, parallel-study
design that incorporated a nested crossover
design between the positive control
(moxifloxacin) and albiglutide placebo. This
design (positive control vs. placebo) provided
adequate power for testing the effect of albiglutide
and demonstrating assay sensitivity, while
decreasing the sample size compared with that
needed with a standard 3-arm parallel study
design.
Albiglutide did not prolong QT intervals in
this study. The QT interval is dependent on the
heart rate and a QT correction factor is required
to normalize changes in QT interval attributable
to heart rate changes. It is currently
acknowledged that Bazett’s method for heart
rate correction (QTcB) of the QT interval is
inappropriate and the reporting of this interval
is therefore no longer required in QT assessment
studies (Q&A #11 in [5]). The use of QT
correction methods, such as QTcB and QTcF
formulas, may also introduce errors in
estimating drug-induced QT prolongation,
secondary to changes in heart rate [20].
Corrections for heart rate using individual
subject data and correction factors have been
developed and per the ICH guidance are
preferred when sufficient QT interval
measurements are available for each subject
over a range of heart rates [6]. The QTcI applies
regression analysis techniques to individual
subject pre-therapy QT and RR interval data
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over a range of heart rates and then applies this
correction to on-treatment QT values. Both
QTcF and QTcI theoretically correct the QT
interval to that which would be observed at a
heart rate of 1 cycle per second (60 bpm). In this
study, an evaluation of QTcF and QTcI
demonstrated that QTcI more appropriately
removed the heart rate dependence of the
corrected QT interval. The threshold of
regulatory concern for a prolonged QT/QTc
interval is around 5 ms with an upper bound
of the 95% CI that excludes 10 ms [6].
Albiglutide, after a single 30-mg dose and at
steady-state concentrations (repeat doses of
50 mg albiglutide), met these criteria.
In the healthy subjects who received
multiple doses of 50 mg albiglutide, there was
a mean placebo-corrected heart rate between
approximately 6 and 8 bpm on Day 39. There
were no apparent changes in systolic or diastolic
blood pressure. GLP-1 receptor agonists have
been reported to increase heart rate in short-
and long-term clinical studies [21]. In clinical
studies with other approved long-acting GLP-1
agonists (exenatide once weekly and
liraglutide), mean increases in heart rate of
4–9 bpm have been observed [22]. An outlier
analysis provided additional evidence that
albiglutide did not prolong the QT interval.
No subjects treated with albiglutide had a QT
interval change-from-baseline value[30 ms or a
QTcI value [450 ms and no treatment-
emergent abnormalities in T-wave morphology
were observed. There was no effect on the QRS
interval; however, the PR interval increased
(*1–5 ms) while on albiglutide treatment.
Moxifloxacin (400 mg) was used as a positive
control tovalidate theabilityof thestudy todetect
a change in the corrected QT interval. Assay
sensitivity was confirmed by the moxifloxacin
response in which the lower bound of the QTc
interval was[5 ms at predefined timepoints after
a single dose. Assay sensitivity was also confirmed
using an alternative baseline to assess the same
duration (40 days) between baseline and ECG
assessment as for the primary analysis. The
observed time-dependent effect on variability
was low when using both the period baseline
and the alternative baseline with the same
duration as for drug assessment. The time-
dependent, between-subject variability was
lower than what was assumed for sample size
calculations (assumed between-subject SD of
12 ms). The observed between-subject variability
for both albiglutide doses and placebo and
moxifloxacin was \12 ms for both baseline
assessments, indicating no gross inadequacies in
the sample size for primary endpoints.
Concentration/QTc modeling demonstrated
a negative relationship between albiglutide
plasma levels and an effect on DDQTcI;
therefore, there was no evidence for QTc
prolongation with increasing albiglutide
exposures. Consistent with findings for
albiglutide, liraglutide also demonstrated no
evidence of a dose–response relation with QTc
changes [15]. Exenatide showed a weak positive
slope of the relationship between QTcF and
plasma concentration data [16]; however, a post
hoc analysis with QTcI did not show a positive
concentration relationship [23]. An infusion of
exenatide was utilized to achieve therapeutic and
supratherapeutic doses in an additional TQT
study [23]; concentration–effect modeling in
this study demonstrated no correlation between
plasma exenatide concentration and QTcI.
Albiglutide was well tolerated by the healthy
subjects in this study. The AE profile suggests
that the AEs were unlikely to have impacted the
QTcI data. The safety profile for this study was
consistent with previous studies with
albiglutide conducted in healthy subjects.
A limitation of the study was that albiglutide
was tested only at therapeutic doses in this study.
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The ICH E14 guideline indicates that
concentrations higher than those achieved with
a therapeutic dose should be tested in a TQT
study unless precluded by safety and tolerability
due to AEs [6]. Given the occurrence of increased
nausea and vomiting at higher doses of
albiglutide, the maximal dose in the QT/QTc
study was restricted to the maximum therapeutic
dose, similar to the dose setting for the QT/QTc
studies for liraglutide [15] and exenatide [16].
Furthermore, the concentration/QTc analysis
does not support that albiglutide at higher
plasma levels would cause QTc prolongation.
In conclusion, albiglutide at clinically relevant
doses up to 50 mg in healthy subjects did not
prolong the QTc interval. An effect on DDQTcI
exceeding the level of regulatory concern (10 ms)
could be confidently excluded with both
albiglutide doses and there was no evidence of
QTc prolongation with increasing albiglutide
exposures. Assay sensitivity was confirmed by
the moxifloxacin QTc response. These data
provide evidence that albiglutide at the
proposed clinical doses is not expected to affect
cardiac repolarization in subjects with T2DM.
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